Page last updated: 2024-08-18

quinuclidines and Obesity

quinuclidines has been researched along with Obesity in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bencherif, M; Hauser, TA; Lippiello, PM; Lucas, R; Marrero, MB; Mazurov, A; Salet, C1
Caballero, F; Elena, M; Fernández, A; Fernández-Checa, JC; García-Ruiz, C; Llacuna, L; Martínez, L; Matías, N; Montfort, CV; Morales, A; Rimola, A1
Bischoff, SC; Haub, S; Hubert, A; Ladel, I; Ritze, Y; Saum, K; Spruss, A; Trautwein, C1

Other Studies

3 other study(ies) available for quinuclidines and Obesity

ArticleYear
An alpha7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 332, Issue:1

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Binding, Competitive; Blood Glucose; Cell Line; Cloning, Molecular; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Electrophysiological Phenomena; Energy Metabolism; Female; Humans; Ligands; Lipid Metabolism; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Structure; Nicotinic Agonists; Obesity; Oocytes; Patch-Clamp Techniques; Quinuclidines; Rats; Receptors, Leptin; Receptors, Nicotinic; Thiophenes; Tumor Necrosis Factor-alpha; Weight Gain; Xenopus laevis

2010
Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury.
    Journal of hepatology, 2011, Volume: 54, Issue:5

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Choline; Choline Deficiency; Disease Models, Animal; Disease Susceptibility; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Glutathione; Heptanoic Acids; Lipotropic Agents; Liver; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mitochondria; Obesity; Pyrroles; Quinuclidines; Reperfusion Injury

2011
Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 339, Issue:3

    Topics: Actins; Animals; Azo Compounds; Drug Evaluation, Preclinical; Duodenum; Endotoxins; Fatty Liver; Indoles; Inflammation; Isoquinolines; Leptin; Liver; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Palonosetron; Proteins; Quinuclidines; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Tropisetron; Tumor Necrosis Factor-alpha

2011